Citius Pharmaceuticals Stock Alpha and Beta Analysis
| CTXR Stock | USD 0.89 0.01 1.11% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Citius Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Citius Pharmaceuticals over a specified time horizon. Remember, high Citius Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Citius Pharmaceuticals' market risk premium analysis include:
Beta 2.8 | Alpha (0.65) | Risk 7.7 | Sharpe Ratio (0.04) | Expected Return (0.32) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Citius Pharmaceuticals Backtesting, Citius Pharmaceuticals Valuation, Citius Pharmaceuticals Correlation, Citius Pharmaceuticals Hype Analysis, Citius Pharmaceuticals Volatility, Citius Pharmaceuticals History and analyze Citius Pharmaceuticals Performance. Citius Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Citius Pharmaceuticals market risk premium is the additional return an investor will receive from holding Citius Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Citius Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Citius Pharmaceuticals' performance over market.| α | -0.65 | β | 2.80 |
Citius Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Citius Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Citius Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Citius Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Citius Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Citius Pharmaceuticals shares will generate the highest return on investment. By understating and applying Citius Pharmaceuticals stock market price indicators, traders can identify Citius Pharmaceuticals position entry and exit signals to maximize returns.
Citius Pharmaceuticals Return and Market Media
The median price of Citius Pharmaceuticals for the period between Sun, Oct 12, 2025 and Sat, Jan 10, 2026 is 1.2 with a coefficient of variation of 21.26. The daily time series for the period is distributed with a sample standard deviation of 0.26, arithmetic mean of 1.21, and mean deviation of 0.21. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Citius Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future | 11/12/2025 |
2 | How Citius Pharmaceuticals Inc. stock reacts to Fed rate cuts - Trade Risk Report Daily Price Action Insights - newser.com | 11/17/2025 |
3 | Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration | 11/21/2025 |
4 | Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN | 12/02/2025 |
5 | Citius Oncology Announces Closing of 18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules | 12/10/2025 |
6 | Gold Edges Lower Omeros Shares Jump | 12/24/2025 |
7 | Contrasting Citius Pharmaceuticals Relmada Therapeutics | 01/09/2026 |
About Citius Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Citius or other stocks. Alpha measures the amount that position in Citius Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Payables Turnover | 0.0383 | 0.0428 | Days Of Inventory On Hand | 13.0K | 11.5K |
Citius Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Citius Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Citius Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Citius Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Citius Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Citius Pharmaceuticals' management manipulating its earnings.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of January 2025 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Citius Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.